AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22592162 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (2 sessions per week for 4 weeks, each lasting 50 minutes)
Number of subjects: 31
Study 22592162 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study 20443801 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded implants
Number of subjects: 11
Study 20443801 — intervention group
Group type: COMPARATOR
Intervention: Early loaded implants
Number of subjects: 11
Study 18777124 — intervention group
Group type: EXPERIMENTAL
Intervention: Home access to PA equipment
Number of subjects: 205
Study 18777124 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 205
Study 18777124 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived satisfaction
Number of subjects: 205
Study 16318157 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated electroacupuncture
Number of subjects: 100
Study 16318157 — intervention group
Group type: COMPARATOR
Intervention: Normal electroacupuncture
Number of subjects: 100
Study 12512664 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment using air abrasion followed by placement of preventive resin restorations
Number of subjects: 93
Study 12512664 — intervention group
Group type: COMPARATOR
Intervention: Control group (no early treatment)
Number of subjects: 93
Study 12512664 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment group
Number of subjects: 93
Study 12512664 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 93
Study 9809925 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (2.5 mg once a day)
Number of subjects: 40
Study 9809925 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (30 mg once a day)
Number of subjects: 40
Study 9809925 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin (0.5 mg once a day)
Number of subjects: 40
Study 9809925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7806412 — intervention group
Group type: EXPERIMENTAL
Intervention: One-appointment root canal therapy using calcium hydroxide
Number of subjects: 0
Study 7806412 — intervention group
Group type: COMPARATOR
Intervention: Two-appointment root canal therapy using calcium hydroxide
Number of subjects: 0
Study 2528492 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin infusion (0.7 mU kg‐1 min‐1 for 8 hours)
Number of subjects: 7
Study 2528492 — intervention group
Group type: COMPARATOR
Intervention: 0.15 mmol/l NaCl solution infusion over 8 hours (Control)
Number of subjects: 7
Study 2528492 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Human insulin and NaCl)
Number of subjects: 7
Study 4804455 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine treatment without dietary restriction
Number of subjects: 6
Study 4804455 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie diet
Number of subjects: 6
Study 4804455 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet with fenfluramine
Number of subjects: 6
Study 31724097 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-0 Polypropylene (PP)
Number of subjects: 0
Study 31724097 — intervention group
Group type: COMPARATOR
Intervention: 5-0 fast absorbing plain gut (FG)
Number of subjects: 0
Study 31630445 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly adalimumab (ADAew)
Number of subjects: 0
Study 31630445 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0
Study 28807505 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported delayed ejaculation (DE)
Number of subjects: 988
Study 28807505 — intervention group
Group type: COMPARATOR
Intervention: No delayed ejaculation (no DE)
Number of subjects: 988
Study 28807505 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejaculation time
Number of subjects: 988
Study 26424327 — intervention group
Group type: EXPERIMENTAL
Intervention: self-management intervention
Number of subjects: 113
Study 26424327 — intervention group
Group type: COMPARATOR
Intervention: education intervention
Number of subjects: 113
Study 23750742 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral naltrexone and brief behavioral counseling
Number of subjects: 200
Study 23750742 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 200
Study 21347224 — intervention group
Group type: EXPERIMENTAL
Intervention: pSG2.HBs vaccine followed by MVA.HBs vaccine
Number of subjects: 72
Study 21347224 — intervention group
Group type: EXPERIMENTAL
Intervention: 3TC therapy
Number of subjects: 72
Study 21347224 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime-boost vaccine regimen (pSG2.HBs and MVA.HBs)
Number of subjects: 72
Study 21347224 — intervention group
Group type: COMPARATOR
Intervention: Control group (Intramuscular rabies vaccine)
Number of subjects: 72
Study 18645683 — intervention group
Group type: EXPERIMENTAL
Intervention: SK3530 (50, 100, or 150 mg)
Number of subjects: 119
Study 18645683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 18645683 — intervention group
Group type: EXPERIMENTAL
Intervention: SK3530
Number of subjects: 119
Study 16446743 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised dietary and lifestyle counselling biannually
Number of subjects: 1062
Study 16446743 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1062
Study 12750654 — intervention group
Group type: EXPERIMENTAL
Intervention: Low back pain >30 days at baseline
Number of subjects: 2000
Study 12750654 — intervention group
Group type: EXPERIMENTAL
Intervention: Low back pain in year 0
Number of subjects: 2000
Study 16497479 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelclair (15 ml applied directly onto the wound 3 times per day, 1 hour before meals for 1 week)
Number of subjects: 60
Study 16497479 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (600 mg 3 times per day for 4 days)
Number of subjects: 60
Study 10225169 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 3.0 mg kg‐1
Number of subjects: 152
Study 10225169 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 1.5 mg kg‐1
Number of subjects: 152
Study 10225169 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 0.3 mg kg‐1
Number of subjects: 152
Study 10225169 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 0.02 ml kg‐1)
Number of subjects: 152
Study 8934303 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 25 mg
Number of subjects: 13
Study 8934303 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 50 mg
Number of subjects: 13
Study 8934303 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine (both doses)
Number of subjects: 13
Study 8934303 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine and Codeine
Number of subjects: 13
Study 8934303 — intervention group
Group type: EXPERIMENTAL
Intervention: C6G, Codeine, M3G
Number of subjects: 13
Study 8934303 — intervention group
Group type: EXPERIMENTAL
Intervention: M3G
Number of subjects: 13
Study 1882280 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I: Methotrexate and fluorouracil once a week and cyclophosphamide every other day for 15 days
Number of subjects: 66
Study 1882280 — intervention group
Group type: COMPARATOR
Intervention: Group II: All drugs given simultaneously once weekly for 15 days
Number of subjects: 66
Study 1882280 — intervention group
Group type: COMPARATOR
Intervention: Group I vs Group II
Number of subjects: 66
Study 6888268 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon administration
Number of subjects: 28
Study 31204837 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 47
Study 31204837 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic therapy
Number of subjects: 47
Study 31204837 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 47
Study 28128967 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective mandibular advancement device
Number of subjects: 150
Study 28128967 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 150
Study 27043756 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape Program intervention (12-month digital health treatment)
Number of subjects: 194
Study 27043756 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 194
Study 25253539 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based coaching program with telephone counseling
Number of subjects: 168
Study 25253539 — intervention group
Group type: COMPARATOR
Intervention: Usual care without web-based coaching
Number of subjects: 168
Study 23114016 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy plus probiotics (Probinul - Cadigroup)
Number of subjects: 68
Study 23114016 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy alone
Number of subjects: 68
Study 19639462 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin (100 mg twice a day)
Number of subjects: 100
Study 19639462 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate (520 mg once a day)
Number of subjects: 100
Study 17478172 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRHa) leuprolide acetate
Number of subjects: 13
Study 17478172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 15235144 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation therapy
Number of subjects: 32
Study 15235144 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 32
Study 12150492 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once-daily
Number of subjects: 0
Study 12150492 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin
Number of subjects: 0
Study 9640148 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% sevoflurane and 60% nitrous oxide in oxygen
Number of subjects: 40
Study 9640148 — intervention group
Group type: COMPARATOR
Intervention: 5% halothane and 60% nitrous oxide in oxygen
Number of subjects: 40
Study 7924363 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbicarb (1 mEq sodium/mL, n = 18)
Number of subjects: 36
Study 7924363 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate (1 mEq sodium/mL, n = 18)
Number of subjects: 36
Study 7924363 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbicarb
Number of subjects: 36
Study 7924363 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate
Number of subjects: 36
Study 2685445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary thrombolytic therapy with avelysine
Number of subjects: 100
Study 2685445 — intervention group
Group type: COMPARATOR
Intervention: Systemic thrombolytic therapy with streptodekase
Number of subjects: 100
Study 30745350 — intervention group
Group type: EXPERIMENTAL
Intervention: Loupes
Number of subjects: 40
Study 30745350 — intervention group
Group type: COMPARATOR
Intervention: No loupes (Control)
Number of subjects: 40
Study 29123351 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with essential oil of orange (4 drops on a pad, replaced every 1 hour for 6 hours)
Number of subjects: 60
Study 29123351 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aromatherapy)
Number of subjects: 60
Study 29123351 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with essential oil of orange
Number of subjects: 60
Study 26247866 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition (fMRI after stress exposure)
Number of subjects: 0
Study 23831862 — intervention group
Group type: EXPERIMENTAL
Intervention: Essence of chicken
Number of subjects: 20
Study 23831862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21130990 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 400 μg
Number of subjects: 1103
Study 21130990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1103
Study 20551490 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of physical activity into core curricula (30 minutes a day, 3 days a week)
Number of subjects: 0
Study 20551490 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no integration of physical activity)
Number of subjects: 0
Study 17685172 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term graphomotor intervention
Number of subjects: 52
Study 17685172 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 15517308 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of alphaS1‐casein hydrolysate (TS)
Number of subjects: 100
Study 15517308 — intervention group
Group type: COMPARATOR
Intervention: Bovine skimmed milk powder (CS)
Number of subjects: 100
Study 12390521 — intervention group
Group type: EXPERIMENTAL
Intervention: Sera containing anti-L-periaxin antibody injected into the endoneurium of rat sciatic nerve
Number of subjects: 29
Study 12390521 — intervention group
Group type: EXPERIMENTAL
Intervention: Sera containing anti-L-periaxin antibody
Number of subjects: 29
Study 12390521 — intervention group
Group type: EXPERIMENTAL
Intervention: Depleted sera of anti-L-periaxin antibodies
Number of subjects: 29
Study 12390521 — intervention group
Group type: COMPARATOR
Intervention: Sera from age-matched control subjects
Number of subjects: 29
Study 12390521 — intervention group
Group type: COMPARATOR
Intervention: Sera from healthy control subjects
Number of subjects: 29
Study 9916056 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrio cholerae 638 (El Tor, Ogawa) strain, doses ranging from 4 x 10(7) to 2 x 10(9) vibrios.
Number of subjects: 56
Study 9916056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 9916056 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrio cholerae 638 (El Tor, Ogawa) strain
Number of subjects: 56
Study 7574044 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose acadesine (0.05 mg.kg‐1.min‐1)
Number of subjects: 633
Study 7574044 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose acadesine (0.1 mg.kg‐1.min‐1)
Number of subjects: 633
Study 7574044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 633
Study 2076720 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetropium bromide 5 mg
Number of subjects: 7
Study 2076720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 6794709 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 24
Study 6794709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31769212 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (6 mg/kg intravenous infusion at week 0, then 90 mg subcutaneous injections every 8 weeks starting at week 8)
Number of subjects: 102
Study 31769212 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (after crossover from placebo)
Number of subjects: 102
Study 31769212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 31769212 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (overall treatment)
Number of subjects: 102
Study 31769212 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 102
Study 30583949 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifuged adipose tissue (CAT) treatment
Number of subjects: 16
Study 30583949 — intervention group
Group type: COMPARATOR
Intervention: Control (no CAT treatment)
Number of subjects: 16
Study 28000225 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin rinses (minimum use of 12 months)
Number of subjects: 125
Study 28000225 — intervention group
Group type: COMPARATOR
Intervention: Control group (no isotretinoin rinses)
Number of subjects: 125
Study 25566704 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous presternal bupivacaine infusion (5 mL/h bupivacaine 0.25%)
Number of subjects: 40
Study 25566704 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 40
Study 23987123 — intervention group
Group type: EXPERIMENTAL
Intervention: Low key group intervention focusing on obesity-related information, alleviation of social isolation, school and vocational integration, and improvement of self-esteem.
Number of subjects: 600
Study 23987123 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment focusing on weight loss.
Number of subjects: 600
Study 21029506 — intervention group
Group type: EXPERIMENTAL
Intervention: DoiT intervention
Number of subjects: 747
Study 21029506 — intervention group
Group type: COMPARATOR
Intervention: Control (water consumption)
Number of subjects: 747
Study 20071288 — intervention group
Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg tablets
Number of subjects: 30
Study 20071288 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 30
Study 17284136 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (mean dose 64.0 ± 23.3 mg, 0.75 mg/kg)
Number of subjects: 41
Study 17284136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 15547531 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated spectroscopic pressure measurements at light (0.2 N), medium (0.4 N), and firm (0.6 N) levels
Number of subjects: 18
Study 12003482 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral-B Battery toothbrush (D4)
Number of subjects: 114
Study 12003482 — intervention group
Group type: COMPARATOR
Intervention: Colgate Actibrush
Number of subjects: 114
Study 12003482 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 114
Study 9398007 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 million units of interferon alfa 2b (IFN‐alpha2b) three times per week for 24 months
Number of subjects: 42
Study 9398007 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 42
Study 8177627 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF)
Number of subjects: 58
Study 8177627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 3221935 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole immunotherapy
Number of subjects: 0
Study 3221935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3221935 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 0
Study 28671712 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 550-mg BD (n=36)
Number of subjects: 54
Study 28671712 — intervention group
Group type: COMPARATOR
Intervention: Placebo BD (n=18)
Number of subjects: 54
Study 27475904 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 18
Study 27475904 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 18
Study 24917547 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3839 single-ascending-dose (SAD) study
Number of subjects: 0
Study 22901586 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 62
Study 22901586 — intervention group
Group type: COMPARATOR
Intervention: External beam radiotherapy
Number of subjects: 62
Study 20551828 — intervention group
Group type: EXPERIMENTAL
Intervention: Written disclosure therapy (WDT) group
Number of subjects: 66
Study 20551828 — intervention group
Group type: COMPARATOR
Intervention: Control group (writing about an emotionally neutral subject)
Number of subjects: 66
Study 19073509 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (T) 20 mg per day orally
Number of subjects: 578
Study 19073509 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (E) 25 mg per day orally
Number of subjects: 578
Study 15898901 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 26
Study 15898901 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 26
Study 11915990 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 1402
Study 11915990 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 1402
Study 9536229 — intervention group
Group type: EXPERIMENTAL
Intervention: Near erythemogenic therapy (70% of the 311 nm MED)
Number of subjects: 13
Study 9536229 — intervention group
Group type: COMPARATOR
Intervention: Far erythemogenic therapy (35% of the 311 nm MED)
Number of subjects: 13
Study 9536229 — intervention group
Group type: EXPERIMENTAL
Intervention: Near erythemogenic therapy
Number of subjects: 13
Study 9536229 — intervention group
Group type: COMPARATOR
Intervention: Far erythemogenic therapy
Number of subjects: 13
Study 7898843 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical prostaglandin E2 (PGE2) gel
Number of subjects: 441
Study 7898843 — intervention group
Group type: COMPARATOR
Intervention: Hygroscopic dilators
Number of subjects: 441
Study 2795521 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical acupuncture needling sites
Number of subjects: 65
Study 2795521 — intervention group
Group type: COMPARATOR
Intervention: Non-classical (sham) needling sites
Number of subjects: 65
Study 40345 — intervention group
Group type: EXPERIMENTAL
Intervention: mequitazine (two 10‐milligram doses a day)
Number of subjects: 12
Study 40345 — intervention group
Group type: EXPERIMENTAL
Intervention: dexchlorpheniramine (two 12‐milligram doses a day)
Number of subjects: 12
Study 40345 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 30998965 — intervention group
Group type: EXPERIMENTAL
Intervention: Video knowledge translation strategy
Number of subjects: 119
Study 30998965 — intervention group
Group type: EXPERIMENTAL
Intervention: Written knowledge translation strategy
Number of subjects: 119
Study 30998965 — intervention group
Group type: COMPARATOR
Intervention: No-information control
Number of subjects: 119
Study 28714735 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranayama plus education
Number of subjects: 43
Study 28714735 — intervention group
Group type: COMPARATOR
Intervention: Education alone (Control)
Number of subjects: 43
Study 28714735 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Pranayama and Control)
Number of subjects: 43
Study 25456442 — intervention group
Group type: COMPARATOR
Intervention: Monocolumn spinal cord stimulation (SCS)
Number of subjects: 115
Study 25456442 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicolumn spinal cord stimulation (SCS)
Number of subjects: 115